+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Effect of endotoxin on tirilazad mesylate (U74006F) pharmacokinetic parameters in neonatal calves

Journal of Veterinary Pharmacology and Therapeutics 16(4): 438-445

Effect of endotoxin on tirilazad mesylate (U74006F) pharmacokinetic parameters in neonatal calves

The pharmacokinetics of the 21-aminosteroid tirilazad mesylate (U74006F) were studied in both healthy and endotoxin-challenged neonatal calves. Group I calves received a 3-h intravenous (i.v.) infusion of sterile saline (250 ml) and tirilazad mesylate (1.5 mg/kg i.v.) 1 h after the start of the saline infusion. Group II calves received tirilazad mesylate 1 h after the start of a 3-h endotoxin (3.25 micrograms/kg) infusion. The data obtained indicate that tirilazad mesylate follows a biexponential equation in neonatal calves. The area-derived volume of distribution (Vdarea) was 9.68 +/- 0.759 l/kg in healthy calves and 6.53 +/- 1.20 l/kg in endotoxin-challenged calves (P < 0.05). Similarly, significant (P < 0.05) decreases in steady-state volume of distribution (Vdss) and central volume (Vc) were observed in endotoxin-challenged calves (5.32 +/- 0.979 l/kg and 1.68 +/- 0.189 l/kg, respectively) compared to healthy calves (7.58 +/- 0.834 l/kg and 2.43 +/- 0.452 l/kg, respectively). A and B were significantly larger in endotoxin-challenged calves than in healthy calves (P < 0.05). Rate constants and their associated half-lives, area under the curve and clearance were not significantly altered by endotoxin challenge. Serum thromboxane generation (ex vivo) was evaluated as a marker of the drug's physiologic activity. There was no significant difference in thromboxane generation during clotting of blood from healthy and endotoxemic calves treated with tirilazad mesylate.

Accession: 002355358

PMID: 8126760

DOI: 10.1111/j.1365-2885.1993.tb00209.x

Download PDF Full Text: Effect of endotoxin on tirilazad mesylate (U74006F) pharmacokinetic parameters in neonatal calves

Related references

Effect of tirilazad mesylate (U74006F) on eicosanoid and tumor necrosis factor generation in healthy and endotoxemic neonatal calves. Circulatory Shock 40(4): 235-242, 1993

Effect of U74006F (Tirilazad Mesylate) in rabbit eyes after argon laser trabeculoplasty. Indian Journal of Ophthalmology 42(3): 149-152, 1994

Effect of delayed administration of U74006F (tirilazad mesylate) on recovery of locomotor function after experimental spinal cord injury. Journal of Neurotrauma 8(3): 187-192, 1991

Protective effect of the 21-aminosteroid lipid peroxidation inhibitor tirilazad mesylate (U74006F) on hepatic endothelium in experimental hemorrhagic shock. Circulatory Shock 40(2): 125-131, 1993

Clinical efficacy of tirilazad mesylate for treatment of endotoxemia in neonatal calves. American Journal of Veterinary Research 53(12): 2305-2310, 1992

The effect of tirilazad mesylate (U74006F) on cerebral oxygen consumption, and reactivity of cerebral blood flow to carbon dioxide in healthy volunteers. Anesthesiology 79(4): 666-671, 1993

Combination therapy with U74006F (tirilazad mesylate), MK-801, insulin and diazepam in transient forebrain ischaemia. Neurological Research 17(2): 132-136, 1995

Effects of new 21-aminosteroid tirilazad mesylate (U74006F) on chronic cerebral vasospasm in a "two-hemorrhage" model of beagle dogs. Neurosurgery 34(6): 1035-9; Discussion 1039, 1994

Effect of repeated administration of tirilazad mesylate on healthy and endotoxemic calves: a pilot study. Canadian Journal of Veterinary Research 58(1): 67-70, 1994

Lack of pharmacokinetic interaction between cimetidine and tirilazad mesylate. Pharmaceutical Research 11(2): 341-344, 1994